U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,781.90
    -23.60 (-1.31%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1966
    +0.0053 (+0.44%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3304
    -0.0052 (-0.39%)
     
  • USD/JPY

    104.0660
    -0.1840 (-0.18%)
     
  • BTC-USD

    16,989.11
    +264.31 (+1.58%)
     
  • CMC Crypto 200

    332.54
    -4.96 (-1.47%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Urovant Sciences Ltd. to Sumitovant Biopharma

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7091/68512_8fde49d774094aee_001full.jpg

To: All Persons or Entities who purchased Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) stock prior to November 12, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Urovant to Sumitovant Biopharma ("Sumitovant"). Sumitovant currently owns 72% of the outstanding shares of Urovant common stock, and under the terms of the merger agreement, will acquire the outstanding shares of Urovant common stock it does not already own at a price of $16.25 per share in cash. To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/urovant-sciences-ltd-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Urovant merger investigation concerns whether the Board of Urovant has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68512